Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CFO Scott Burrows sold 2,500 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $40.65, for a total value of $101,625.00. Following the sale, the chief financial officer owned 97,994 shares in the company, valued at approximately $3,983,456.10. This represents a 2.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Spyre Therapeutics Stock Performance
Shares of NASDAQ SYRE opened at $40.07 on Wednesday. Spyre Therapeutics, Inc. has a fifty-two week low of $10.91 and a fifty-two week high of $45.76. The stock has a market cap of $3.15 billion, a PE ratio of -19.26 and a beta of 3.09. The stock has a fifty day moving average of $34.73 and a 200-day moving average of $26.74.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.04). On average, sell-side analysts predict that Spyre Therapeutics, Inc. will post -4.46 EPS for the current year.
Wall Street Analyst Weigh In
Several equities analysts recently commented on SYRE shares. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Spyre Therapeutics in a research note on Monday, December 29th. Mizuho upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a research report on Thursday, December 18th. BTIG Research reaffirmed a "buy" rating and issued a $70.00 price target on shares of Spyre Therapeutics in a report on Friday, February 20th. Wall Street Zen lowered Spyre Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, February 21st. Finally, Citigroup began coverage on Spyre Therapeutics in a research note on Wednesday, December 17th. They issued a "buy" rating and a $64.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Spyre Therapeutics currently has a consensus rating of "Buy" and an average price target of $53.44.
Read Our Latest Stock Analysis on SYRE
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Spyre Therapeutics by 18.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,018 shares of the company's stock valued at $442,000 after purchasing an additional 4,277 shares in the last quarter. CWM LLC boosted its holdings in shares of Spyre Therapeutics by 357.8% in the 2nd quarter. CWM LLC now owns 1,712 shares of the company's stock worth $26,000 after purchasing an additional 1,338 shares in the last quarter. AlphaQuest LLC increased its position in shares of Spyre Therapeutics by 30.8% during the 2nd quarter. AlphaQuest LLC now owns 4,174 shares of the company's stock valued at $62,000 after purchasing an additional 983 shares during the last quarter. ProShare Advisors LLC increased its position in shares of Spyre Therapeutics by 9.7% during the 2nd quarter. ProShare Advisors LLC now owns 12,479 shares of the company's stock valued at $187,000 after purchasing an additional 1,101 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Spyre Therapeutics by 15.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,227,232 shares of the company's stock valued at $18,373,000 after buying an additional 167,669 shares in the last quarter. 80.39% of the stock is currently owned by hedge funds and other institutional investors.
About Spyre Therapeutics
(
Get Free Report)
Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.
Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
